Professional Certificate Course in Drug Regulatory Affairs

Bridge the pharmaceutical industry and regulatory authorities, regulatory affairs professionals guide drug registration from development to post-marketing across markets while ensuring safety and compliance.

The course explains how drug regulatory affairs ensure medicinal products meet quality, safety, and efficacy standards, oversee compliant manufacturing and distribution, and uphold accurate promotional practices.

Explore how the drug regulatory affairs team guides licensing, product registration, pricing control, quality, and pharmacovigilance from development to post marketing.

Learn about the main regulatory applications, including IND, NDA, BLA, and related marketing authorization, GMP certification, and intellectual property filings (patent, copyright, trademark).

Explore ind, nda, and anda concepts used in USA drug regulation, including ind types (investigator, emergency, treatment) and the data, labeling, and orange book considerations for nda and anda approvals.

Understand generic drug products as comparable to innovator drugs in dosage form, strength, route, quality and performance, file DMFs with FDA to support NDA and IND submissions after patent expiry.

Explains 505(b)(2) as a type of NDA that relies on existing data, contains a full safety and effectiveness report, enabling faster and cheaper approvals and new differentiated products.

Differentiate NDA and 505(b)(2) applications: the NDA relies on the applicant's reference data, while 505(b)(2) covers new dosage forms, routes, or indications and is a type of NDA.

Understand how marketing authorization applications (MAA) secure regulatory approval for new active substances and for existing substances, and how the active substance master file (ASMF) protects confidential API information.

Explore ICH guidelines for preparing registration dossiers, including CTD structure and five modules, and the M4 family for quality, safety, nonclinical, and clinical data.

The Orange Book lists FDA-approved drugs with therapeutic equivalence codes, excluding biologics. The Hatch-Waxman Act created the modern generic drug approval system and 180-day exclusivity for first to file NDA.

Explore 180-day exclusivity under Hatch-Waxman, how first generic applications gain market protection, alongside dossiers and CMC in regulatory affairs for drug approvals.

Explore CDSCO as the national regulator for cosmetics, pharmaceuticals and medical devices, its structure, key divisions, and essential acts and schedules guiding quality, licensing, and clinical trials.

Learn the U.S. FDA's role in protecting public health, enforcing the federal food, drug, and cosmetic act, and navigating major acts and CFR titles—foods, drugs, biologics, cosmetics, and medical devices.

Explore emea, the european medicines agency, for evaluating, authorising, and monitoring medicines in the eu and eea, and navigate eudralex volumes covering gmp, pharmacovigilance, and risk management.

Explore the UK medicines and healthcare products regulatory agency (MHRA), formed in 2003 from MCA and MDA, merged with NIBSC in 2013, overseeing medicines, devices, three centers, and eight committees.

Discover how the Therapeutic Goods Administration regulates import, export, manufacture, and advertising of therapeutic goods in Australia, ensuring GMP-compliant production and timely access to therapeutic advances.

Explore the four ICH guideline categories—quality (Q1–Q14), safety (S1–S13), efficacy (E1–E22, including pharmacovigilance and clinical study reports), and multidisciplinary topics (MedDRA, CTD, eCTD)—and learn how these harmonize pharmaceutical requirements.

Explore CTD and eCTD, organizing quality, safety, and efficacy data into a harmonized electronic format across modules 1–5 for streamlined regulatory submissions.

Explore how quality assurance proactively monitors stages to prevent defects, while quality control inspects products to ensure standards, with qa as process-focused, proactive function and qc as product-focused, reactive function.

Regulatory affairs evolve and remain resilient through mergers, acquisitions, and recessions, serving as the interface between pharma and regulators, with outsourcing options to CRO/BPO and essential soft and hard skills.

After this certificate course in drug regulatory affairs, reissue your completion certificate from your profile and share it on LinkedIn to inspire others; download slides and use Q&A to learn.